Clinical variables at baseline and changes from baseline to 3-month and 6-month assessments after adjustments for the propensity score
| Baseline | 3-month changes | 6-month changes | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Adalimumab (n = 84) | Adalimumab and MTX (n = 99) | p Value | Adalimumab (n = 76) | Adalimumab and MTX (n = 89) | p Value* | Adalimumab (n = 76) | Adalimumab amd MTX (n = 89) | p Value* | |
| CRP, C reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; M-HAQ, Modified Health Assessment Questionnaire; SJC, swollen joint count (28 joints); TJC, tender joint count (28 joints); VAS, Visual Analogue Scale. | |||||||||
| Values are presented as mean (SD). | |||||||||
| *p Values are from analysis of covariance after adjustments for the propensity score. | |||||||||
| ESR | 34.6 (25.7) | 29.5 (21.1) | 0.16 | −2.5 (22.1) | −4.6 (21.6) | 0.61 | −3.3 (21.4) | −8.1 (20.9) | 0.21 |
| CRP | 28.7 (31.3) | 27.0 (31.0) | 0.73 | −0.7 (37.0) | −11.7 (36.2) | 0.11 | −0.2 (28.0) | −14.0 (35.7) | 0.03 |
| SJC | 8.4 (5.9) | 9.7 (5.7) | 0.12 | −1.9 (5.9) | −5.4 (5.8) | 0.001 | −2.1 (6.5) | −6.1 (6.4) | <0.001 |
| TJC | 10.2 (7.5) | 9.9 (7.2) | 0.73 | −1.1 (8.4) | −4.8 (8.3) | 0.05 | −2.5 (9.1) | −6.0 (8.8) | 0.03 |
| VAS p. global | 54.1 (24.3) | 55.4 (23.6) | 0.72 | −9.2 (30.3) | −17.2 (29.7) | 0.14 | −8.3 (32.7) | −19.1 (32.0) | 0.05 |
| VAS i. global | 49.4 (19.1) | 48.6 (19.6) | 0.78 | −17.2 (24.7) | −22.7 (24.2) | 0.21 | −16.8 (26.7) | −25.9 (26.3) | 0.04 |
| DAS28 | 5.5 (1.2) | 5.4 (1.2) | 0.60 | −0.66 (1.6) | −1.44 (1.5) | 0.01 | −0.61 (1.7) | −1.66 (1.7) | 0.001 |
| M-HAQ | 1.89 (0.57) | 1.84 (0.45) | 0.52 | −0.09 (0.52) | −0.27 (0.52) | 0.06 | −0.11 (0.53) | −0.29 (0.53) | 0.05 |